Skip to main content
PMC home page
SpringerPlus logoLink to SpringerPlus
. 2016 Sep 7;5(1):1508. doi: 10.1186/s40064-016-3197-y

TNF-α gene polymorphisms and expression

Radwa R El-Tahan 1, Ahmed M Ghoneim 1,✉, Noha El-Mashad 2
PMCID: PMC5014780  PMID: 27652081

Abstract

Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine with an important role in the pathogenesis of several diseases. Its encoding gene is located in the short arm of chromosome 6 in the major histocompatibility complex class III region. Most of the TNF-α gene polymorphisms are located in its promoter region and they are thought to affect the susceptibility and/or severity of different human diseases. This review summarizes the data related to the association between TNF-α gene and its receptor polymorphisms, and the development of autoimmune diseases. Among these polymorphisms the −308G/A TNF-α promotor polymorphism has been associated several times with the the development of autoimmune diseases, however some discrepant results have been recorded. The other TNF-α gene polymorphisms had little or no association with autoimmune diseases. Current results about the molecules controlling TNF-α expression are also presented. The discrepancy between different records could be related partly to either the differences in the ethnic origin or number of the studied individuals, or the abundance and activation of other molecules that interact with the TNF-α promotor region or other elements.

Keywords: TNF-α, Polymorphisms, Expression, Autoimmune diseases

Background

Tumor necrosis factor (TNF), first termed by O’Malley et al. (1962), was initially reported to induce programmed cell death or apoptosis. Currently, this molecule is thought to be involved in the regulation of many important cellular processes such as proliferation, differentiation, growth, and the immune response (Hayashi et al. 2013). TNF-α is produced by various types of cells including macrophages, monocytes, neutrophils, T cells, and NK-cells. The gene encoding TNF-α is located in the class III region of the major histocompatibility complex on chromosome 6 between the HLA-B and HLA-DR genes (Zhang et al. 2013). TNF binds to two types of outer membrane bound receptors on the target cells, TNFR1 and TNFR2, and triggers the cell survival and proinflammatory NF-κB and MAP kinases activations (Locksley et al. 2001). The molecule activates phagocytes to engulf and clear infectious agents and cellular debris (Elahi et al. 2009). It also increases the expression of adhesion molecules on the vascular endothelium to allow immune cells, in particular neutrophils and macrophages, to translocate to the sites of tissue damage and infection (Barbara et al. 1996).

The roles that TNF-α play seem to be contradictory and this was related to the genetic polymorphisms in the genes regulating its production and effect (Elahi et al. 2009), and the polymorphisms in TNF locus itself. It has been reported that the genetic alterations in the TNF-α locus are involved in high TNF-α production (Tsukamoto et al. 1998).

Several TNF-α polymorphisms have been identified inside the TNF-α promoter at the positions, relative to the transcription start site, −1031 (T/C), −863 (C/A), −857 (C/A), −851 (C/T), −419 (G/C), −376 (G/A), −308 (G/A), −238 (G/A), −162 (G/A), and −49 (G/A) (Elahi et al. 2009).

In this article, we review the association between the genetic polymorphisms in TNF-α and the development of autoimmune diseases, and the relation between these polymorphisms and TNF-α expression.

Polymorphisms in TNF-α receptors

TNF-α interacts with the TNF receptors TNF-RI and TNF-RII (Bayley et al. 2003). TNF-α receptors (TNF-Rs) are active both in membrane-bound and soluble forms, and the soluble receptors act as physiological attenuators of TNF activity (Aderka 1996). With respect to their chromosomal location, TNF-RI gene is located at 12p13 and the TNF-RII gene is located at 1p36.2 (Bayley et al. 2003).

With respect to the relation between TNF-Rs and autoimmune diseases, no association was reported between TNF-RI +36 and rheumatoid arthritis (RA) in Dutch and UK Caucasian population as approved by Bayley et al. (2003) and Barton et al. (2001) respectively. No association was found between the TNF-RII +1690 polymorphism and susceptibility to or severity of RA in the Dutch population (Bayley et al. 2003).

However, TNF-RII 196M/R SNP was found to be associated with susceptibility to familial RA (Barton et al. 2001; Dieude et al. 2002), but not associated with sporadic RA severity in Caucasian patients (Van der Helm-van Mil et al. 2004). Glossop et al. (2003) and Constantin et al. (2004) have reported conflicting results about considering TNF-RII 196 M/R SNP as a genetic factor in RA severity. The 676TT genotype of TNF-α RII was related to a better response to anti-TNF-α drugs when compared to 676TG (Ongaro et al. 2008).

Association between TNF-α genetic polymorphisms and autoimmune diseases

Systemic lupus erthymatosus (SLE)

In SLE patients, an increased level of TNF-α was reported and strongly correlated with the parameters of disease activity (Studnicka-Benke et al. 1996). A significant genetic association between TNF-α promoter −308A/G polymorphism and SLE susceptibility in Asian populations, and in European-derived populations was detected in Zou et al. (2011) and Lee et al. (2006) meta-analysis respectively.

The −308A allele of TNF-α was associated with the production of TNF-α and susceptibility to SLE (Rood et al. 2000; Sullivan et al. 1997). This allele contributed to susceptibility to SLE in South African patients (Wang et al. 1999).

Piotrowski et al. (2015) indicated the presence of significant contribution of TNF-α −308 A allele to arthritis and renal SLE manifestation, and that the TNF-α −308 G/A polymorphism may be a HLA-DRB1*03:01 haplotype-dependent genetic risk factor for SLE in a cohort of Polish population.

The +489A allele of TNF-α was also thought to have a genetic contribution to the susceptibility to SLE in the Chinese population (Lin et al. 2009).

Rheumatoid arthritis (RA)

TNF-α is thought to play a central role in inflammation and it has been directly implicated in the pathogenesis of RA (Feldmann et al. 1990). High concentrations of TNF-α were detected in serum and synovial fluid of RA patients and TNF-α blood concentration correlated with RA disease activity (Nemec et al. 2008).

Studies on the association between −238G/A and −308G/A TNF polymorphisms and Juvenile Idiopathic Arthritis (JIA) showed conflicting results. For example, the −238 G/A polymorphism did not have an effect on the patients’ outcome in either Turkish or Czech patients while the −308 G/A polymorphism was significantly associated with a poor outcome in the Turkish group but not in the Czech patients (Ozen et al. 2002) or with systemic JIA in Japanese population (Date et al. 1999). However, TNF-α −308A allele was significantly associated with JIA (JimÊnez-Morales et al. 2009), with systemic JIA (Modesto et al. 2005). Date et al. (1999) demonstrated that the −863A, −1013C, and −857T alleles were significantly higher in systemic JIA Japanese patients.

TNF-α was also considered as a major candidate gene in psoriatic arthritis (PsA) (Kane and FitzGerald 2004) as TNF-α was present in high levels in serum, synovial fluid, and synovial membrane in patients with PsA (Danning et al. 2000; Partsch et al. 1997). However, studies on the association between TNF-α polymorphisms and PsA showed conflicting results. A strong association between −308G/A and −238G/A promoter polymorphisms and susceptibility to PsA was demonstrated in some studies (Mössner et al. 2005; Rahman et al. 2006). In contrast, Murdaca et al. (2014) did not find significant association between −238 and −308G/A SNPs and PsA in Italian patients but they found a significant association between +489A allele and both PsA susceptibility and severity. Rahman et al. (2006) could not detect any significant association between −1031T/C, −863C/A and −857C/T SNPs and PsA.

Also, studies on the relation between TNF-α polymorphisms and RA showed conflicting results. For example, susceptibility to RA was associated with the −308A allele in some studies (JimÊnez-Morales et al. 2009; Lee et al. 2007), with the G allele in others (Mosaad et al. 2011), but neither with A allele nor G allele in others (Ates et al. 2008; Gambhir et al. 2010; Khanna et al. 2006; Nemec et al. 2008; Rezaieyazdi et al. 2007).

Heterozygous genotype GA of −308A/G SNP was found to be associated with more severe course of RA disease (Cvetkovic et al. 2002), with increased number of erosions, and with the progression of radiographic damage in patients with early seropositive RA (Khanna et al. 2006). RA severity was associated with the presence of −308A allele (Mosaad et al. 2011; Rodríguez-Carreón et al. 2005) and with −308G allele (Nemec et al. 2008). The −308G allele showed a trend toward worse radiological outcome by 5 years in patients with inflammatory arthritis as indicated by the presence/absence of erosions (Barton et al. 2004). In Han Chinese population, susceptibility of RA increased in patients with TNF-α −308G allele, especially in the females, and the patients containing both HLA-DRB1*04 and TNF-α–308 GG genotype showed a significant increase in risk for RA regardless of their sex (Li et al. 2015). On the other hand, in a cohort of Argentinean patients with RA, the −308A allele was neither associated with suscetibility to RA nor with the course and outcome of the disease (Aranda et al. 2014). In addition, there was no significant association between −308 G/A polymorphism and RA risk in a cohort of Bulgarian population (Manolova et al. 2014).

−238G/A polymorphism was associated with more severe course of RA (Fabris et al. 2002), however, Barton et al. (2004) showed that both −238G/A and −376G/A were not associated with RA severity. No association was reported between −238G/A and −376G/A polymorphisms and susceptibility to RA in Egyptian population (Mousa et al. 2014). Barton et al. (2004) failed to find any difference in either allele or genotype frequences of −1031, −863, −857, +489, +851 and +1304 SNPs between patients with inflammatory arthritis developing erosions and those remaining non erosive at 5 years.

Fonseca et al. (2007) demonstrated an association between −238, −308, −857, and −863 SNPs and systemic manifestations, functional status, radiological damage, work disability, and joint surgeries.

Ankylosing spondylitis (AS)

TNF-α level in blood and its expression by peripheral T cells correlated well with AS activity (Bal et al. 2007; Rudwaleit et al. 2001). Studies on the relation between TNF-α SNPs and AS have shown controversial results. For example, TNF-α polymorphisms had no independent effect on AS susceptibility (Chung et al. 2011; Li et al. 2010) but their modulating effect on TNF-α expression were well relevant to the phenotypic diversity in AS (Lee and Song 2009; Poddubnyy et al. 2011). In contrast, Vargas-Alarcón et al. (2006) and Shiau et al. (2007) showed an association of −308G/A polymorphism with susceptibility to AS. Moreover, the A allele was thought to have a protective role against AS (Chung et al. 2011; Nossent et al. 2014), and was associated with a lower risk of developing AS, and with the age at disease onset, disease severity and response to anti-TNF treatment (Manolova et al. 2014).

In conclusion, the data from the studies on TNF-α genetic polymorphisms seem to vary from one study to another. This variation could be related to the differences in the ethnic orgin or the number of the indivisulas under study. Although these polymorphisms do affect the expression level of TNF-α, the activation and abundance of other molecules that interact directly or indirectly with the promotor sequence must affect the expression of TNF- α.

Control of TNF-α gene expression

Several studies tried to address the relation between TNF-α polymorphisms and its expression, and the mechanisms controlling its expressions in many cell types and diseases. High TNF-α expression level was associated with the −238G allele in multiple sclerosis patients (Huizinga et al. 1997) and with −863A and −1031C alleles in healthy Japanese and non-Japaneses individuals (Higuchi et al. 1998). While the −238A allele was reported to down regulate TNF-α expression (Kaluza et al. 2000). In appearently healthy individuals, van Heel et al. (2002) demonstrated that the −857T (but not the −857C) allele inhibits TNF-α transcription through its strong binding with the transcription factor OCT1, which blocks the interaction of nuclear factor-kappa-B (NF-κB) to the nearby region −873 to −863 (Fig. 1).

Fig. 1.

Fig. 1

Open in a new tab

Schematic representation showing some of the molecules thought to be involved in the interaction with TNF-α promoter region. The transcriptional induction of TNF-α is thought to be controlled by some transcription factors, including the transcription factor OCT1, the nuclear factor κB (NF-κB), the signal transducer and transcription activator (PIAS1) and activator protein-1 (AP-1). The transcription factor OCT1 can strongly bind with the allele -857T (but not the -857C) and thus blocks the interaction of NF-κB to the nearby region -873 to -863 leading to inhibition of TNF-α transcription. PIAS1 possesses SUMO E3 ligase activity and can repress NF-κB by blocking the DNA-binding activity of NF-κB to TNF-α promoter. Ang II can activate the 2 transcription factors NF-kB and AP-1that are important in mediating TNF-α gene expression. Alleles associated with upregulation of TNF-α gene are designated with arrows with heads directed up while those alleles associated with downregulation are designated with arrows with heads directed down. Molecules involved in the posttranscriptional and posttranslational control of TNF-α are mentioned in the text and not shown here

Mousa et al. (2014) detected a significant increase of TNF-α expression in RA patients compared to healthy individuals, but this increase in expression was not linked to a certain allele of the −238G/A and −376G/A SNPs. Besides, several polymorphisms in some TNF-linked genes were also thought to regulate the expression of TNF directly or indirectly (Abraham and Kroeger 1999).

According to Liu and Shuai (2008), TNF-α can be autoregulated by activating PIAS1 [a member of the protein inhibitor of activated STAT1 (signal transducer and activator of transcription 1) family] SUMO E3 ligase. It is though that once activated, PIAS1 is then recruited to the TNF-α gene promoter to repress transcription (Liu and Shuai 2008).

The neurohormonal molecule, angiotensin II (Ang II), was thought to play a role in up regulation of TNF-α gene expression as Ang II activates two transcriptional factors that are important in mediating TNF-α gene expression, nuclear factor (NF)-kB and activator protein-1 (AP-1) (Chua et al. 1998; Hernandez-Presa et al. 1997; Ruiz-Ortega et al. 1998) (Fig. 1). Angiotensin II also provokes TNF biosynthesis in various nonmyocyte cell types (Ferreri et al. 1998; Klahr and Morrissey 1998).

Oxidized low density lipoprotein (LDL) and LDL were demonstrated to decrease TNF mRNA expression in NK cells (Malorni et al. 1997). Mitogen-activated Protein Kinase (MAPK) has been found to play a central role in the induced TNF-α expression in monocytes, macrophages, mast cells and T cells (Hoffmeyer et al. 1999; Ishizuka et al. 1997; Swantek et al. 1997; Zhang et al. 1997; Zhu et al. 2000).

The 3′ UTR of TNF-α contains a sequence element that is though to affect posttranslational control of TNF through mRNA stability and translation efficiency (Elahi et al. 2009). TNF mRNA has two protein-binding regions (Hel et al. 1998, 1996) located in the AU-rich element (ARE) within 3′ UTR (Garnon et al. 2005). Both AREs were reported to interact with several proteins including TIAR and AUF1 (DeMaria and Brewer 1996; Gueydan et al. 1999) which control TNF mRNA post transcription. Pituitary adenylate cyclase-activating polypeptide is another protein that was found to inhibit TNF-α expression (Manecka et al. 2014).

cAMP has been reported to play an important role in regulating TNF-α expression, for example the elevation of cellular cAMP suppresses TNF-α production (Gobejishvili et al. 2006; Zidek 1999).

Interferon regulatory factor-5 (IRF5) has been also reported to play a key role in the induction of TNF-α (Barnes et al. 2002). Krausgruber et al. (2010) has reported that TNF secretion in human monocyte-derived dendritic cells is mediated by cooperative action of IRF5 and RelA at the 5′ upstream and 3′ downstream regions of the TNF gene.

In conclusion, the expression of TNF-α seems to be controlled by the activation of other cellular molecules including signal transducer molecules, nuclear factors and second messenger molecules. More studies to address the interaction between these molecules and TNF-α are required to finally map a TNF-α pathway. Profiling the expression of the key molecules inside such pathway can open an avenue to control TNF-α over or downregulation.

Conclusion

TNF-α plays an important role in the pathogenesis of autoimmune diseases. Several studies show that TNF-α gene promoter polymorphisms affect the susceptibility and/or severity of autoimmune diseases. Polymorphisms in the TNF receptors does not seem to be associated with the development of autoimmune diseases. The −308 G/A TNF-α promotor polymorphism seems to be highly associated with the development of these diseases, however some discrepant results have been recorded. Other TNF-α gene polymorphisms had little or no association with autoimmune diseases. This discrepancy might be explained by the differences in the ethnic orgin or number of the studied individuals. TNF-α gene expression is controlled by the presence of some polymorphisms in its promoter region and by several types of signalling molecules or nuclear factors that interact with the TNF-α promotor region or other elements.

Authors’ contributions

RE searched the literature and wrote the initial draft of the manuscript. AG structured, revised and finalized the manuscript. NM took part in revising the manuscript. All authors read and approved the final manuscript

Acknowledgements

The authors would like to thank Mr. Mohamed A. Bedeer, IT unit, Faculty of Science, Damietta University for the figure design.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

Ang II

angiotensin II

ARE

AU-rich elements

AS

ankylosing spondylitis

AUF1

AU-rich element RNA-binding protein 1

HLA-B

human leukocyte antigen-B

HLA-DR

human leukocyte antigen-DR

JIA

juvenile idiopathic arthritis

LDL

low density lipoprotein

MAP kinases

mitogen-activated protein kinases

NF-κB

nuclear factor kappa-light-chain-enhancer of activated B cells

NK-cells

natural killer cells

OCT1

organic cation transporter 1

PIAS 1

protein inhibitor of activated STAT-1

STAT-1

signal transducer and activator of transcription-1

PSA

psoriatic arthritis

RA

rheumatoid arthritis

SLE

systemic lupus erthymatosus

SNPs

single nucleotide polymorphisms

SUMO E3 ligase

small ubiquitin-like modifier E3 ligase

TNFR-I

tumor necrosis factor receptor-1

TNF-α

tumor necrosis factor alpha

TIAR

T-cell-restricted intracellular antigen 1-related protein

Contributor Information

Radwa R. El-Tahan, Email: ElTahan.Radwa@yahoo.com

Ahmed M. Ghoneim, Phone: +20572403981, Email: am_ghoneim@du.edu.eg

Noha El-Mashad, Email: nmashad@hotmail.com.

References

  1. Abraham LJ, Kroeger KM. Impact of the-308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol. 1999;66:562–566. doi: 10.1002/jlb.66.4.562. [DOI] [PubMed] [Google Scholar]
  2. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996;7:231–240. doi: 10.1016/S1359-6101(96)00026-3. [DOI] [PubMed] [Google Scholar]
  3. Aranda F, Perés Wingeyer SD, Schneeberger E, et al. The −308 G/A polymorphism in the tumor necrosis factor-α gene is not associated with development and progression of rheumatoid arthritis in Argentinean patients. Int J Rheum Dis. 2014 doi: 10.1111/1756-185X.12343. [DOI] [PubMed] [Google Scholar]
  4. Ates O, Hatemi G, Hamuryudan V, Topal-Sarikaya A. Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients. Clin Rheumatol. 2008;27:1243–1248. doi: 10.1007/s10067-008-0893-1. [DOI] [PubMed] [Google Scholar]
  5. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol. 2007;26:211–215. doi: 10.1007/s10067-006-0283-5. [DOI] [PubMed] [Google Scholar]
  6. Barbara JA, Van Ostade X, Lopez A. Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective. Immunol Cell Biol. 1996;74:434–443. doi: 10.1038/icb.1996.73. [DOI] [PubMed] [Google Scholar]
  7. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol. 2002;22:5721–5740. doi: 10.1128/MCB.22.16.5721-5740.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Barton A, John S, Ollier WER, Silman A, Worthington J. Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. Arthritis Rheum. 2001;44:61–65. doi: 10.1002/1529-0131(200101)44:1<61::AID-ANR9>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  9. Barton A, Platt H, Salway F, Symmons D, Barrett E, Bukhari M, Lunt M, Zeggini E, Eyre Hinks A, Tellam D, Brintnell B, Ollier W, Worthington J, Silman A. Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. Ann Rheum Dis. 2004;63:280–284. doi: 10.1136/ard.2003.008680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bayley JP, Bakker AM, Kaijzel EL, Huizinga TWJ, Verweij CL. Association of polymorphisms of the tumour necrosis factor receptors I and II and rheumatoid arthritis. Rheumatology. 2003;42:969–971. doi: 10.1093/rheumatology/keg267. [DOI] [PubMed] [Google Scholar]
  11. Chua CC, Hamdy RC, Chua BHL. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. BBA. Mol Cell Res. 1998;1401:187–194. doi: 10.1016/s0167-4889(97)00129-8. [DOI] [PubMed] [Google Scholar]
  12. Chung W-T, Choe J-Y, Jang WC, Park SM, Ahn YC, Yoon IK, Kim T-H, Nam Y-H, Park S-H, Lee S-W, Kim S-K. Polymorphisms of tumor necrosis factor-α promoter region for susceptibility to HLA-B27-positive ankylosing spondylitis in Korean population. Rheumatol Int. 2011;31:1167–1175. doi: 10.1007/s00296-010-1434-1. [DOI] [PubMed] [Google Scholar]
  13. Constantin A, Dieude P, Lauwers-Cances V, Jamard B, Maziéres B, Cambon-Thomsen A, Cornélis F, Cantagrel A. Tumor necrosis factor receptor II gene polymorphism and severity of rheumatoid arthritis. Arthritis Rheum. 2004;5:742–747. doi: 10.1002/art.20113. [DOI] [PubMed] [Google Scholar]
  14. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, Rantapaa-Dahlqvist S, Lefvert AK. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes. J Rheumatol. 2002;29:212–219. [PubMed] [Google Scholar]
  15. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000;43:1244–1256. doi: 10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  16. Date Y, Seki N, Kamizono S, Higuchi T, Hirata T, Miyata K, Ohkuni M, Tatsuzawa O, Yokota S, Joo K, Ueda K, Sasazuki T, Kimura A, Itoh K, Kato H. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5′-flanking region of the TNFalpha gene and HLA genes. Arthritis Rheum. 1999;42:2577–2582. doi: 10.1002/1529-0131(199912)42:12<2577::AID-ANR10>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  17. DeMaria CT, Brewer G. AUF1 binding affinity to A + U-rich elements correlates with rapid mRNA degradation. J Biol Chem. 1996;271:12179–12184. doi: 10.1074/jbc.271.21.12179. [DOI] [PubMed] [Google Scholar]
  18. Dieude P, Petit E, Cailleau-Moindrault S, Osorio J, Pierlot C, Martinez M, Fauré S, Alibert O, Lasbleiz S, Toma C, Bardin T, Prum B, Cornélis F, European Consortium on Rheumatoid Arthritis Families Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity. Arthritis Rheum. 2002;46:2039–2044. doi: 10.1002/art.10101. [DOI] [PubMed] [Google Scholar]
  19. Elahi MM, Asotra K, Matata BM, Mastana SS. Tumor necrosis factor alpha −308 gene locus promoter polymorphism: an analysis of association with health and disease. BBA Mol Basis Dis. 2009;1792:163–172. doi: 10.1016/j.bbadis.2009.01.007. [DOI] [PubMed] [Google Scholar]
  20. Fabris M, Di PE, D’Elia A, Damante G, Sinigaglia L, Ferraccioli G. Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol. 2002;29:29–33. [PubMed] [Google Scholar]
  21. Feldmann M, Brennan FM, Chantry D, Haworth C, Turner M, Abney E, Buchan G, Barrett K, Barkley D, Chu A. Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis. 1990;49:480–486. [PubMed] [Google Scholar]
  22. Ferreri NR, Escalante BA, Zhao Y, An S-J, McGiff JC. Angiotensin II induces TNF production by the thick ascending limb: functional implications. Am J Physiol Renal Physiol. 1998;274:F148–F155. doi: 10.1152/ajprenal.1998.274.1.F148. [DOI] [PubMed] [Google Scholar]
  23. Fonseca JE, Cavaleiro J, Teles J, Sousa E, Andreozzi VL, Antunes M, Amaral-Turkman MA, Canhão H, Mourão AF, Lopes J, Caetano-Lopes J, Weinmann P, Sobral M, Nero P, Saavedra MJ, Malcata A, Cruz M, Melo R, Braña A, Miranda L, Patto JV, Barcelos A, Silva J, Santos LM, Figueiredo G, Rodrigues M, Jesus H, Quintal A, Carvalho T, Silva JA, et al. Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter. Arthritis Res Therapy. 2007;9:R37. doi: 10.1186/ar2173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Gambhir D, Lawrence A, Aggarwal A, Misra R, Mandal SK, Naik S. Association of tumor necrosis factor alpha and IL-10 promoter polymorphisms with rheumatoid arthritis in North Indian population. Rheumatol Int. 2010;30:1211–1217. doi: 10.1007/s00296-009-1131-0. [DOI] [PubMed] [Google Scholar]
  25. Garnon J, Lachance C, Di Marco S, Hel Z, Marion D, Ruiz MC, Newkirk MM, Khandjian EW, Radzioch D. Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. J Biol Chem. 2005;280:5750–5763. doi: 10.1074/jbc.M401988200. [DOI] [PubMed] [Google Scholar]
  26. Glossop JR, Nixon NB, Dawes PT, Hassell AB, Mattey DL. No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. J Rheumatol. 2003;30:1406–1409. [PubMed] [Google Scholar]
  27. Gobejishvili L, Barve S, Joshi-Barve S, Uriarte S, Song Z, McClain C. Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NF-κB activity and TNF expression: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2006;291:G681–G688. doi: 10.1152/ajpgi.00098.2006. [DOI] [PubMed] [Google Scholar]
  28. Gueydan C, Droogmans L, Chalon P, Huez G, Caput D, Kruys V. Identification of TIAR as a protein binding to the translational regulatory AU-rich element of tumor necrosis factor α mRNA. J Biol Chem. 1999;274:2322–2326. doi: 10.1074/jbc.274.4.2322. [DOI] [PubMed] [Google Scholar]
  29. Hayashi K, Piras V, Tabata S, Tomita M, Selvarajoo K. A systems biology approach to suppress TNF-induced proinflammatory gene expressions. Cell Commun Signal. 2013;11:84. doi: 10.1186/1478-811X-11-84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hel Z, Skamene E, Radzioch D. Two distinct regions in the 3′ untranslated region of tumor necrosis factor alpha mRNA form complexes with macrophage proteins. Mol Cell Biol. 1996;16:5579. doi: 10.1128/MCB.16.10.5579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hel Z, Di Marco S, Radzioch D. Characterization of the RNA binding proteins forming complexes with a novel putative regulatory region in the 3′-UTR of TNF-α mRNA. Nucleic Acids Res. 1998;26:2803–2812. doi: 10.1093/nar/26.11.2803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532–1541. doi: 10.1161/01.CIR.95.6.1532. [DOI] [PubMed] [Google Scholar]
  33. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-α gene in Japanese. Tissue Antigens. 1998;51:605–612. doi: 10.1111/j.1399-0039.1998.tb03002.x. [DOI] [PubMed] [Google Scholar]
  34. Hoffmeyer A, Grosse-Wilde A, Flory E, Neufeld B, Kunz M, Rapp UR, Ludwig S. Different mitogen-activated protein kinase signaling pathways cooperate to regulate tumor necrosis factor α gene expression in T lymphocytes. J Biol Chem. 1999;274:4319–4327. doi: 10.1074/jbc.274.7.4319. [DOI] [PubMed] [Google Scholar]
  35. Huizinga TWJ, Westendorp RGJ, Bollen ELEM, Keijsers V, Brinkman BMN, Langermans JAM, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, García-Gonzalez A, van Oosten BW, Polman CH, Peña AS. TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol. 1997;72:149–153. doi: 10.1016/S0165-5728(96)00182-8. [DOI] [PubMed] [Google Scholar]
  36. Ishizuka T, Terada N, Gerwins P, Hamelmann E, Oshiba A, Fanger GR, Johnson GL, Gelfand EW. Mast cell tumor necrosis factor α production is regulated by MEK kinases. Proc Natl Acad Sci USA. 1997;94:6358–6363. doi: 10.1073/pnas.94.12.6358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. JimÊnez-Morales S, Velázquez-Cruz R, RamÎrez-Bello J, Bonilla-González E, Romero-Hidalgo S, Escamilla-Guerrero G, Cuevas F, Espinosa-Rosales F, Martínez-Aguilar NE, Gómez-Vera J, Baca V, Orozco L. Tumor necrosis factor–α is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population. Hum Immunol. 2009;70:251–256. doi: 10.1016/j.humimm.2009.01.027. [DOI] [PubMed] [Google Scholar]
  38. Kaluza W, Reuss E, Grossmann S, Hug R, Schopf RE, Galle PR, Maerker-Hermann E, Hoehler T. Different transcriptional activity and in vitro TNF-α production in psoriasis patients carrying the TNF-α 238A promoter polymorphism. J Invest Dermatol. 2000;114:1180–1183. doi: 10.1046/j.1523-1747.2000.00001.x. [DOI] [PubMed] [Google Scholar]
  39. Kane D, FitzGerald O. Tumor necrosis factor-α in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective. Curr Rheumatol Rep. 2004;6:292–298. doi: 10.1007/s11926-004-0041-0. [DOI] [PubMed] [Google Scholar]
  40. Khanna D, Wu H, Park G, Gersuk V, Gold RH, Nepom GT, Wong WK, Sharp JT, Reed EF, Paulus HE, Tsao BP, for the Western Consortium of Practicing Rheumatologists Association of tumor necrosis factor α polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis Rheum. 2006;54:1105–1116. doi: 10.1002/art.21750. [DOI] [PubMed] [Google Scholar]
  41. Klahr S, Morrissey J. Angiotensin II and gene expression in the kidney. Am J Kidney Dis. 1998;31:171–176. doi: 10.1053/ajkd.1998.v31.pm9428470. [DOI] [PubMed] [Google Scholar]
  42. Krausgruber T, Saliba D, Ryzhakov G, Lanfrancotti A, Blazek K, Udalova IA. IRF5 is required for late-phase TNF secretion by human dendritic cells. Blood. 2010;115:4421–4430. doi: 10.1182/blood-2010-01-263020. [DOI] [PubMed] [Google Scholar]
  43. Lee YH, Song GG. Lack of association of TNF-α promoter polymorphisms with ankylosing spondylitis: a meta-analysis. Rheumatology. 2009;48:1359–1362. doi: 10.1093/rheumatology/kep260. [DOI] [PubMed] [Google Scholar]
  44. Lee YH, Harley JB, Nath SK. Meta-analysis of TNF-alpha promoter −308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet. 2006;14:364–371. doi: 10.1038/sj.ejhg.5201566. [DOI] [PubMed] [Google Scholar]
  45. Lee YH, Ji JD, Song GG. Tumor necrosis factor-alpha promoter −308 A/G polymorphism and rheumatoid arthritis susceptibility: a metaanalysis. J Rheumatol. 2007;34:43–49. [PubMed] [Google Scholar]
  46. Li B, Wang P, Li H. The association between TNF-α promoter polymorphisms and ankylosing spondylitis: a meta-analysis. Clin Rheumatol. 2010;29:983–990. doi: 10.1007/s10067-010-1499-y. [DOI] [PubMed] [Google Scholar]
  47. Li F, Xie X, Chen J, Gao J, Lu F. Association of TNF-α gene polymorphisms with the risk of rheumatoid arthritis in Han Chinese population from Hunan. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2015;40:945. doi: 10.11817/j.issn.1672-7347.2015.09.001. [DOI] [PubMed] [Google Scholar]
  48. Lin YJ, Chen RH, Wan L, Sheu JJ-C, Huang C-M, Lin C-W, Chen S-Y, Lai C-H, Lan Y-C, Hsueh K-C, Tsai C-H, Lin T-H, Huang Y-M, Chao K, Chen D-Y, Tsai F-J. Association of TNF-α gene polymorphisms with systemic lupus erythematosus in Taiwanese patients. Lupus. 2009;18:974–979. doi: 10.1177/0961203309105361. [DOI] [PubMed] [Google Scholar]
  49. Liu B, Shuai K. Targeting the PIAS1 SUMO ligase pathway to control inflammation. Trends Pharmacol Sci. 2008;29:505–509. doi: 10.1016/j.tips.2008.07.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501. doi: 10.1016/S0092-8674(01)00237-9. [DOI] [PubMed] [Google Scholar]
  51. Malorni W, Straface E, Di Genova G, Fattorossi A, Rivabene R, Camponeschi B, Masella R, Viora M. Oxidized low-density lipoproteins affect natural killer cell activity by impairing cytoskeleton function and altering the cytokine network. Exp Cell Res. 1997;236:436–445. doi: 10.1006/excr.1997.3736. [DOI] [PubMed] [Google Scholar]
  52. Manecka D-L, Lelièvre V, Anouar Y. Inhibition of constitutive TNF production is associated with PACAP-mediated differentiation in PC12 cells. FEBS Lett. 2014;588:3008–3014. doi: 10.1016/j.febslet.2014.06.009. [DOI] [PubMed] [Google Scholar]
  53. Manolova I, Ivanova M, Stoilov R, Rashkov R, Stanilova S. Association of single nucleotide polymorphism at position −308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis. Biotechnol Biotechnol Equip. 2014;28:1108–1114. doi: 10.1080/13102818.2014.972147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Modesto C, Patino-Garcia A, Sotillo-Pineiro E, Merino J, García-Consuegra J, Merino R, Rua MJ, Sierrasesúmaga L, Arnal C. TNF-α promoter gene polymorphisms in Spanish children with persistent oligoarticular and systemic-onset juvenile idiopathic arthritis. Scand J Rheumatol. 2005;34:451–454. doi: 10.1080/03009740510026652. [DOI] [PubMed] [Google Scholar]
  55. Mosaad YM, Abdelsalam A, El-bassiony SR. Association of tumour necrosis factor-alpha −308 G/A promoter polymorphism with susceptibility and disease profile of rheumatoid arthritis. Int J Immunogenet. 2011;38:427–433. doi: 10.1111/j.1744-313X.2011.01028.x. [DOI] [PubMed] [Google Scholar]
  56. Mössner R, Kingo K, Kleensang A, Krüger U, König I, Silm H, Westphal GA, Reich K. Association of TNF −238 and −308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol. 2005;124:282–284. doi: 10.1111/j.0022-202X.2004.23556.x. [DOI] [PubMed] [Google Scholar]
  57. Mousa AK, Ghoneim AM, Noha B, Ahmed E. TNF-α genetic polymorphisms and its expression in Egyptian rheumatoid arthritis patients. Am J Life Sci. 2014;2:234–240. doi: 10.11648/j.ajls.20140204.17. [DOI] [Google Scholar]
  58. Murdaca G, Gulli R, Spanò F, Lantieri F, Burlando M, Parodi A, Mandich P, Puppo F. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol. 2014;134:2503–2509. doi: 10.1038/jid.2014.123. [DOI] [PubMed] [Google Scholar]
  59. Nemec P, Pavkova-Goldbergova M, Stouracova M, Vasku A, Soucek M, Gatterova J. Polymorphism in the tumor necrosis factor-α gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clin Rheumatol. 2008;27:59–65. doi: 10.1007/s10067-007-0653-7. [DOI] [PubMed] [Google Scholar]
  60. Nossent JC, Sagen-Johnsen S, Bakland G. Tumor Necrosis factor–α promoter −308/238 polymorphism association with less severe disease in Ankylosing Spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response. J Rheumatol. 2014;41:1675–1682. doi: 10.3899/jrheum.131315. [DOI] [PubMed] [Google Scholar]
  61. O’Malley WE, Achinstein B, Shear MJ. Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. J Natl Cancer Inst. 1962;29:1169–1175. [Google Scholar]
  62. Ongaro A, De Mattei M, Pellati A, Caruso A, Ferretti S, Masieri F, Fotinidi M, Farina I, Trotta F, Padovan M. Can tumor necrosis factor receptor II gene 676T > G polymorphism predict the response grading to anti-TNFα therapy in rheumatoid arthritis? Rheumatol Int. 2008;28:901–908. doi: 10.1007/s00296-008-0552-5. [DOI] [PubMed] [Google Scholar]
  63. Ozen S, Alikasifoglu M, Bakkaloglu A, Duzova A, Jarosova K, Nemcova D, Besbas N, Vencovsky J, Tuncbilek E. Tumour necrosis factor α G → A − 238 and G → A − 308 polymorphisms in juvenile idiopathic arthritis. Rheumatology. 2002;41:223–227. doi: 10.1093/rheumatology/41.2.223. [DOI] [PubMed] [Google Scholar]
  64. Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997;24:518–523. [PubMed] [Google Scholar]
  65. Piotrowski P, Wudarski M, Sowinska A, Olesinska M, Jagodzinski PP. TNF-308 G/A polymorphism and risk of systemic lupus erythematosus in the Polish population. Mod Rheumatol. 2015;25:719–723. doi: 10.3109/14397595.2015.1008778. [DOI] [PubMed] [Google Scholar]
  66. Poddubnyy DA, Märker-Hermann E, Kaluza-Schilling W, Zeidler H, Braun J, Listing J, Sieper J, Rudwaleit M. Relation of HLA-B27, tumor necrosis factor-α promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis—a comprehensive genotype-phenotype analysis from an observational cohort. J Rheumatol. 2011;38:2436–2441. doi: 10.3899/jrheum.110130. [DOI] [PubMed] [Google Scholar]
  67. Rahman P, Siannis F, Butt C, Farewell V, Peddle L, Pellett F, Gladman D. TNFα polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis. 2006;65:919–923. doi: 10.1136/ard.2005.039164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Rezaieyazdi Z, Afshari JT, Sandooghi M, Mohajer F. Tumour necrosis factor a −308 promoter polymorphism in patients with rheumatoid arthritis. Rheumatol Int. 2007;28:189–191. doi: 10.1007/s00296-007-0444-0. [DOI] [PubMed] [Google Scholar]
  69. Rodríguez-Carreón AA, Zúñiga J, Hernández-Pacheco G, Rodríguez-Pérez J, Pérez-Hernández N, de Oca J, Cardiel MH, Granados J, Vargas-Alarcón G. Tumor necrosis factor-alpha −308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in Mexicans. J Autoimmun. 2005;24:63–68. doi: 10.1016/j.jaut.2004.11.002. [DOI] [PubMed] [Google Scholar]
  70. Rood MJ, Van Krugten MV, Zanelli E, Van Der Linden M, Keijsers V, Schreuder G, Verduyn W, Westendorp RGJ, De Vries RRP, Breedveld FC, Verweij CL, Huizinga TWJ. TNF-308A and HLA–DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2000;43:129–134. doi: 10.1002/1529-0131(200001)43:1<129::AID-ANR16>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  71. Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, Sieper J, Braun J. Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis. 2001;60:36–42. doi: 10.1136/ard.60.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-κB activation and monocyte chemoattractant protein-1 synthesis. J Immunol. 1998;161:430–439. [PubMed] [Google Scholar]
  73. Shiau M-Y, Lo M-K, Chang C-P, Yang T-P, Ho K-T, Chang Y-H. Association of tumour necrosis factor α promoter polymorphisms with ankylosing spondylitis in Taiwan. Ann Rheum Dis. 2007;66:562–563. doi: 10.1136/ard.2006.065888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Rheumatology. 1996;35:1067–1074. doi: 10.1093/rheumatology/35.11.1067. [DOI] [PubMed] [Google Scholar]
  75. Sullivan KE, Wooten C, Schmeckpeper BJ, Goldman D, Petri MA. A promoter polymorphism of tumor necrosis factor α associated with systemic lupus erythematosus in African-Americans. Arthritis Rheum. 1997;40:2207–2211. doi: 10.1002/art.1780401215. [DOI] [PubMed] [Google Scholar]
  76. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol. 1997;17:6274–6282. doi: 10.1128/MCB.17.11.6274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Tsukamoto K, Ohta N, Shirai Y, Emi M. A highly polymorphic CA repeat marker at the human tumor necrosis factor alpha (TNFAα) locus. J Hum Genet. 1998;43:278–279. doi: 10.1007/s100380050090. [DOI] [PubMed] [Google Scholar]
  78. Van der Helm-van Mil AHM, Dieude P, Schonkeren JJM, Cornelis F, Huizinga TWJ. No association between tumour necrosis factor receptor type 2 gene polymorphism and rheumatoid arthritis severity: a comparison of the extremes of phenotypes. Rheumatology. 2004;43:1232–1234. doi: 10.1093/rheumatology/keh314. [DOI] [PubMed] [Google Scholar]
  79. van Heel DA, Udalova IA, De Silva AP, McGovern DP, Kinouchi Y, Hull J, Lench NJ, Cardon LR, Carey AH, Jewell DP. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-κB transcription factors. Hum Mol Genet. 2002;11:1281–1289. doi: 10.1093/hmg/11.11.1281. [DOI] [PubMed] [Google Scholar]
  80. Vargas-Alarcón G, Casasola-Vargas J, Rodríguez-Pérez JM, Huerta-Sil G, Pérez-Hernández N, Londoño J, Pacheco-Tena C, Cardiel MH, Granados J, Burgos-Vargas R. Tumor necrosis factor-α promoter polymorphisms in mexican patients with spondyloarthritis. Hum Immunol. 2006;67:826–832. doi: 10.1016/j.humimm.2006.07.009. [DOI] [PubMed] [Google Scholar]
  81. Wang M, Dong Y, Huang S. Study on the association between tumor necrosis factor alpha gene polymorphism and systemic lupus erythematosus. Zhonghua Nei Ke Za Zhi. 1999;38:393–396. [PubMed] [Google Scholar]
  82. Zhang C, Baumgartner RA, Yamada K, Beaven MA. Mitogen-activated Protein (MAP) kinase regulates production of tumor necrosis factor-α and release of arachidonic acid in mast cells indications of communication between p38 and p42 Map kinases. J Biol Chem. 1997;272:13397–13402. doi: 10.1074/jbc.272.20.13397. [DOI] [PubMed] [Google Scholar]
  83. Zhang B-B, Liu X-Z, Sun J, Yin Y-W, Sun Q-Q. Association between TNF α gene polymorphisms and the risk of duodenal ulcer: a meta-analysis. PLoS One. 2013;8:e57167. doi: 10.1371/journal.pone.0057167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Zhu W, Downey JS, Gu J, Di Padova F, Gram H, Han J. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J Immunol. 2000;164:6349–6358. doi: 10.4049/jimmunol.164.12.6349. [DOI] [PubMed] [Google Scholar]
  85. Zidek Z. Adenosine-cyclic AMP pathways and cytokine expression. Eur Cytokine Netw. 1999;10:319–328. [PubMed] [Google Scholar]
  86. Zou Y-F, Feng X-L, Tao J-H, Su H, Pan F-M, Liao F-F, Fan Y, Ye D-Q. Meta-analysis of TNF-α promoter–308A/G polymorphism and SLE susceptibility in Asian populations. Rheumatol Int. 2011;31:1055–1064. doi: 10.1007/s00296-010-1392-7. [DOI] [PubMed] [Google Scholar]

Articles from SpringerPlus are provided here courtesy of Springer-Verlag

RESOURCES